Gyroscope Therapeutics, a British gene therapy company that has U.S. operations in King of Prussia, has raised $148 million in venture capital funding.
The five-year-old company has now raised about $265 million over three funding rounds since its inception.
Gyroscope’s Series C financing was led by Forbion’s Growth Opportunities Fund. Other investors are Sofinnova Investments, funds and accounts advised by T. Rowe Price Associates, Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona.
The five-year-old company plans to use the proceeds from the stock sale to advance the development of its lead gene therapy candidate, GT005, a potential treatment for geographic atrophy secondary to age-related macular degeneration.
Read the full article at: www.bizjournals.com
Latest posts by Chris Frew (see all)
- Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
- Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
- SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
- Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
- D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021